Literature DB >> 10414837

Production gains from health care: what should be included in cost-effectiveness analyses?

J A Olsen1, J Richardson.   

Abstract

Recent literature has been concerned with the correct measurement of the 'indirect costs and benefits' of health care as well as the issue of including these items in economic evaluations. This article considers the question of which 'indirect benefits' to include in cost effectiveness analysis and cost utility analysis. Within the context of a collectively financed health scheme the relevant issues include not only the size of the net resource costs of providing health care but also which costs and benefits the society is prepared to consider in its assessment of health services. The strong preference for 'equal access for equal need' implies that some production gains may have to be disregarded in the social welfare function. We introduce the notion of socially relevant and socially irrelevant production gains. The analysis suggests that the magnitude of the socially relevant part of the production gains may vary between countries as it depends, first, upon differences in patients' potential contributions to the rest of society (tax rates), and second, the strength of preferences for equity.

Entities:  

Mesh:

Year:  1999        PMID: 10414837     DOI: 10.1016/s0277-9536(99)00116-1

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  20 in total

Review 1.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

2.  Justice and the allocation of healthcare resources: should indirect, non-health effects count?

Authors:  Kasper Lippert-Rasmussen; Sigurd Lauridsen
Journal:  Med Health Care Philos       Date:  2010-08

Review 3.  Methods to assess the costs and health effects of interventions for improving health in developing countries.

Authors:  David B Evans; Tessa Tan-Torres Edejer; Taghreed Adam; Stephen S Lim
Journal:  BMJ       Date:  2005-11-12

4.  Productivity costs in health-state valuations : does explicit instruction matter?

Authors:  Marieke Krol; Werner Brouwer; Pedram Sendi
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Variation in the methodological approach to productivity cost valuation: the case of prostate cancer.

Authors:  Paul Hanly; Rebecca Maguire; Frances Drummond; Linda Sharp
Journal:  Eur J Health Econ       Date:  2019-08-23

Review 6.  Productivity costs in economic evaluations: past, present, future.

Authors:  Marieke Krol; Werner Brouwer; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

7.  How to estimate productivity costs in economic evaluations.

Authors:  Marieke Krol; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

Review 8.  Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.

Authors:  Marieke Krol; Jocé Papenburg; Marc Koopmanschap; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

9.  Can economic evaluation in telemedicine be trusted? A systematic review of the literature.

Authors:  Trine S Bergmo
Journal:  Cost Eff Resour Alloc       Date:  2009-10-24

10.  Simulation of the cost-effectiveness of malaria vaccines.

Authors:  Fabrizio Tediosi; Nicolas Maire; Melissa Penny; Alain Studer; Thomas A Smith
Journal:  Malar J       Date:  2009-06-08       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.